Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.
Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.
复制标题
DOI：
10.1183/16000617.0194-2021
复制
发表时间：
2021-12-31
期刊：
影响因子：
--
通讯作者：
Northwestern Comprehensive COVID Center Consortium
中科院分区：
文献类型：
--
作者：
Mylvaganam RJ;Bailey JI;Sznajder JI;Sala MA;Northwestern Comprehensive COVID Center Consortium
Acute manifestations of SARS-CoV-2 infection continue to impact the lives of many across the world. Post-acute sequelae of coronavirus disease 2019 (COVID-19) may affect 10–30% of survivors of COVID-19, and post-acute sequelae of COVID-19 (PASC)-pulmonary fibrosis is a long-term outcome associated with major morbidity. Data from prior coronavirus outbreaks (severe acute respiratory syndrome and Middle East respiratory syndrome) suggest that pulmonary fibrosis will contribute to long-term respiratory morbidity, suggesting that PASC-pulmonary fibrosis should be thoroughly screened for through pulmonary function testing and cross-sectional imaging. As data accumulates on the unique pathobiologic mechanisms underlying critical COVID-19, a focus on corollaries to the subacute and chronic profibrotic phenotype must be sought as well. Key aspects of acute COVID-19 pathobiology that may account for increased rates of pulmonary fibrosis include monocyte/macrophage–T-cell circuits, profibrotic RNA transcriptomics, protracted elevated levels of inflammatory cytokines, and duration of illness and ventilation. Mechanistic understanding of PASC-pulmonary fibrosis will be central in determining therapeutic options and will ultimately play a role in transplant considerations. Well-designed cohort studies and prospective clinical registries are needed. Clinicians, researchers and healthcare systems must actively address this complication of PASC to minimise disability, maximise quality of life and confront a post-COVID-19 global health crisis. A complication of COVID-19, PASC-pulmonary fibrosis, has the potential to become a global respiratory health crisis. Dedicated surveillance, mechanistic understanding and clinical and research efforts are needed to confront this emerging sequela of COVID-19. https://bit.ly/3GEyB04
登录
查看更多内容
影响因子：
8.8
作者：
Burnham EL;Hyzy RC;Paine R 3rd;Coley C 2nd;Kelly AM;Quint LE;Lynch D;Janssen WJ;Moss M;Standiford TJ
通讯作者：
Standiford TJ
DOI：
10.1183/09031936.00196412
发表时间：
2014-01
期刊：
The European respiratory journal
影响因子：
--
作者：
Burnham EL;Janssen WJ;Riches DW;Moss M;Downey GP
通讯作者：
Downey GP
影响因子：
17.1
作者：
Bharat A;Querrey M;Markov NS;Kim S;Kurihara C;Garza-Castillon R;Manerikar A;Shilatifard A;Tomic R;Politanska Y;Abdala-Valencia H;Yeldandi AV;Lomasney JW;Misharin AV;Budinger GRS
通讯作者：
Budinger GRS
影响因子：
4.6
作者：
D'Cruz, Rebecca F.;Waller, Michael D.;Jolley, Caroline J.
通讯作者：
Jolley, Caroline J.
影响因子：
158.5
作者：
Ackermann, Maximilian;Verleden, Stijn E.;Jonigk, Danny
通讯作者：
Jonigk, Danny